There's going to be some ugly margin calls starting to emerge across the bourse during this rout. NEU have a number of organic catalysts via trial updates to buck the broader market sentiment. Quarterly Daybue sales will no doubt act as an additional pivot. With 70% of the expanding pool of diagnosed patients in the US who have not yet tried treatment, take-up data will provide meaningful confidence around NEUs forecast cashflow strength. The active buy-back will assist to bolster the financials in the interim. Of the AUD$50 million, AUD 29,547,627.99 has been completed. As it stands, 4.92% of the companies issued shares has been short sold. In the interim, put the tin hats on, where the casualties from this barrage will appear over coming months. Capital markets will be headless for a time, thankfully for NEU they don't need development funds.
NEU Price at posting:
$9.04 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)